• Probenecid: From Transporter Biology to Translation

  2026-09-10

  Probenecid is more than an MRP inhibitor: it is a multidimensional mechanistic probe linking drug efflux, pannexin-1 signaling, lysosomal injury, and neuroinflammation. This article presents a translational framework for using 4-(dipropylsulfamoyl)benzoic acid to study multidrug resistance reversal in leukemia and neuroprotection in cerebral ischemia/reperfusion injury while controlling for pharmacological complexity.

• Atropo-Enantioselective Suzuki Synthesis of a Biaryl

  2026-09-10

  Herrbach and colleagues developed a catalytic asymmetric route to an axially chiral biaryl related to the antimitotic alkaloid rhazinilam. The study’s central advance was an intermolecular Suzuki coupling using chiral phosphine ligands, with binaphthyl ligand 7a furnishing the nonbridged precursor in up to 40% enantiomeric excess and establishing a useful strategy for biologically relevant atropisomers.

• Cyanine 5-dCTP for High-Contrast DNA Labeling

  2026-09-09

  Cyanine 5-dCTP adds a red-fluorescent readout to PCR, DNA fluorescent probe synthesis, and enzymatic oligonucleotide workflows. This guide connects Cy5 labeling with ordered DNA-framework strategies, emphasizing practical reaction design, controls, storage, and troubleshooting.

• PPM-18 for NF-κB/iNOS Workflows

  2026-09-09

  PPM-18 is a pathway-focused tool for separating NF-κB-driven iNOS expression from direct nitric oxide synthase inhibition. This guide shows how to build reproducible inflammation, immune-response, and sepsis research workflows while using the CCK-8s atrial study to improve time-resolved assay design.

• YM 58483 (BTP2): A Causal SOCE Assay Strategy

  2026-09-08

  YM 58483 (BTP2) is a powerful research tool for resolving how store-operated Ca2+ entry controls NFAT, IL-2, and fibrotic signaling. This article develops a causal assay framework that connects T-cell experiments with ORAI2-dependent salivary-gland fibrosis research while emphasizing interpretation, controls, and translational limits.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-09-07

  The reference study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase reduces circulating 14,15-EET, suppresses Nrf2-ARE antioxidant signaling, and promotes osteoclast differentiation. By combining patient samples, an ovariectomy-induced mouse model, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics, the work provides a mechanistic framework for studying redox imbalance in osteoporosis.

• LRPPRC–Dasatinib Dual OXPHOS Disruption

  2026-09-07

  The 2026 reference study identifies dasatinib as a synergistic partner for LRPPRC inhibition and shows that the combination suppresses oxidative phosphorylation through complementary effects on mitochondrial- and nuclear-encoded OXPHOS programs. Its screening and mechanistic framework supports biomarker-guided investigation of dual-genome metabolic targeting, while remaining limited to predominantly preclinical cell-model evidence.

• Cy3-UTP for Dynamic RNA Labeling and Kinetics

  2026-09-05

  Cy3-UTP enables covalent fluorescent labeling during transcription, connecting routine RNA production with imaging, interaction assays, and real-time conformational analysis. Its strongest use case is a controlled fluorescence workflow in which label density, position, and photostability are optimized rather than treated as fixed properties.

• SB 202190: Practical p38 MAP Kinase Workflows

  2026-09-04

  SB 202190 (FHPI) is a cell-permeable p38 MAP kinase inhibitor for separating inflammatory signaling, stress responses, and cell-death phenotypes in cultured cells. This practical guide connects its ATP-competitive activity with apoptosis assay design, RIPK1 pathway questions, cancer therapeutics research, and neuroinflammation workflows.

• ER-Targeted Peptide Self-Assembly in Cancer Cells

  2026-09-04

  The reference study develops an alkaline-phosphatase-instructed peptide that self-assembles at the endoplasmic reticulum after incorporating a p-toluenesulfonamide targeting group. This design selectively increases ER stress and cancer-cell death through apoptosis and necroptosis while reducing the concentration limitation associated with intracellular peptide self-assembly.

• Bortezomib (PS-341) in Proteasome Research

  2026-09-04

  Bortezomib (PS-341) turns proteasome inhibition into a practical tool for connecting protein turnover with apoptosis, invasion, and treatment response. This workflow-focused guide shows how to use it alongside viability, apoptosis, and pathway assays to interrogate the MAPK10–KRT16 axis in cancer models.

• VX-765 Workflows for Caspase-1 Research

  2026-09-03

  VX-765 enables selective interrogation of caspase-1-driven cytokine maturation and pyroptotic death across biochemical, cellular, and disease-model workflows. This guide combines practical assay design with time-resolved death analysis inspired by modern functional-genomic screening.

• TPCA-1: An IKK-2 Inhibitor for Inflammation Studies

  2026-09-02

  TPCA-1 is a selective IKK-2 inhibitor for connecting NF-κB activity with cytokine output, inflammatory phenotypes, and regulated cell-death assays. Its strong kinase selectivity and defined monocyte and arthritis-model performance make it useful for mechanism-first inflammation research when paired with orthogonal viability and phosphorylation readouts.

• LDH Cytotoxicity Assay Kit: Practical Guide

  2026-09-02

  The LDH Cytotoxicity Assay Kit (K2228) provides a non-radioactive approach to cell cytotoxicity measurement by quantifying LDH released into culture medium after membrane damage. It is useful for comparative cell damage studies, but it should not be used alone to identify apoptosis mechanisms, establish absolute cell counts, or support automated high-throughput claims without laboratory validation.

• KU-60019: ATM Kinase Inhibitor Workflow

  2026-09-01

  KU-60019 enables selective ATM kinase inhibition for dissecting DNA damage response, radiation sensitivity, and glioma invasion phenotypes. This workflow combines pathway-level validation with functional assays while separating established product evidence from exploratory cross-domain hypotheses.

8612 records 1/575 page Next 12345 下5页 Last page